Preparation and evaluation of zolmitriptan submicron emulsion for rapid and effective nasal absorption in beagle dogs

References

• MacLennan SJ, Cambridge D, Whiting MV, Marston C, Martin GR. (1998). Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine. Eur J Pharmacol, 361:191–197.
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. (2004). Zolmitriptan (Zomig). Expert Rev Neurother, 4:33–41.
   PubMedGoogle Scholar
• Jain R, Nabar S, Dandekar P, Patravale V. (2010). Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm Res, 27:655–664.
   PubMed Web of Science ®Google Scholar
• Vyas TK, Babbar AK, Sharma RK, Misra A. (2005). Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J Drug Target, 13:317–324.
   PubMed Web of Science ®Google Scholar
• Volans GN. (1978). Migraine and drug absorption. Clin Pharmacokinet, 3:313–318.
   PubMed Web of Science ®Google Scholar
• Dahlöf CG, Boes-Hansen S, Cederberg CG, Hardebo JE, Henriksson A. (1998). How does sumatriptan nasal spray perform in clinical practice? Cephalalgia, 18:278–282.
   PubMed Web of Science ®Google Scholar
• Uemura N, Onishi T, Mitaniyama A, Kaneko T, Ninomiya K, Nakamura K et al. (2005). Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig, 25:199–208.
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Brandes J, Eikermann A. (2003). Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache, 43:19–26.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Hamelsky SW, Dayno JM. (2002). What do patients with migraine want from acute migraine treatment? Headache, 42 (Suppl 1):3–9.
   PubMedGoogle Scholar
• Yates R, Nairn K, Dixon R, Seaber E. (2002). Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J Clin Pharmacol, 42:1237–1243.
   PubMed Web of Science ®Google Scholar
• Yates R, Sörensen J, Bergström M, Antoni G, Nairn K, Kemp J et al. (2005). Distribution of intranasal C-zolmitriptan assessed by positron emission tomography. Cephalalgia, 25:1103–1109.
   PubMed Web of Science ®Google Scholar
• Kågedal M, Zingmark P-H, Hedlund C, Yates R. (2005). True nasopharyngeal absorption of zolmitriptan following administration of zolmitriptan nasal spray in healthy male volunteers. Am J Drug Deliv, 3:133–140.
   Google Scholar
• Ko KT, Needham TE, Zia H. (1998). Emulsion formulations of testosterone for nasal administration. J Microencapsul, 15:197–205.
   PubMed Web of Science ®Google Scholar
• Kararli TT, Needham TE, Schoenhard G, Baron DA, Schmidt RE, Katz B et al. (1992). Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations. Pharm Res, 9:1024–1028.
   PubMed Web of Science ®Google Scholar
• Yu C, Meng J, Chen J, Tang X. (2009). Preparation of ergoloid mesylate submicron emulsions for enhancing nasal absorption and reducing nasal ciliotoxicity. Int J Pharm, 375:16–21.
   PubMed Web of Science ®Google Scholar
• Aikawa K, Matsumoto K, Uda H, Tanaka S, Shimamura H, Aramaki Y et al. (1998). Prolonged release of drug from o/w emulsion and residence in rat nasal cavity. Pharm Dev Technol, 3:461–469.
   PubMedGoogle Scholar
• Lu Y, Zhang Y, Yang Z, Tang X. (2009). Formulation of an intravenous emulsion loaded with a clarithromycin–phospholipid complex and its pharmacokinetics in rats. Int J Pharm, 366:160–169.
   PubMed Web of Science ®Google Scholar
• Komatsu H, Kitajima A, Okada S. (1995). Pharmaceutical characterization of commercially available intravenous fat emulsions: estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy. Chem Pharm Bull, 43:1412–1415.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Y, Tang X, Zhang H. (2009). Determination of entrapment efficiency and drug phase distribution of submicron emulsions loaded silybin. J Microencapsul, 26:180–186.
   PubMed Web of Science ®Google Scholar
• Illum L. (2002). Nasal drug delivery: new developments and strategies. Drug Discov Today, 7:1184–1189.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Jiang X, Jiang W, Lu W, Su L, Shi Z. (2004). Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm, 275:85–96.
   PubMed Web of Science ®Google Scholar
• Arora P, Sharma S, Garg S. (2002). Permeability issues in nasal drug delivery. Drug Discov Today, 7:967–975.
   PubMed Web of Science ®Google Scholar
• Jumaa M, Müller BW. (2002). Parenteral emulsions stabilized with a mixture of phospholipids and PEG-660-12-hydroxy-stearate: evaluation of accelerated and long-term stability. Eur J Pharm Biopharm, 54:207–212.
   PubMed Web of Science ®Google Scholar
• Furubayashi T, Inoue D, Kamaguchi A, Higashi Y, Sakane T. (2007). Influence of formulation viscosity on drug absorption following nasal application in rats. Drug Metab Pharmacokinet, 22:206–211.
   PubMed Web of Science ®Google Scholar